Investor Presentaiton

Investor presentation First three months of 2017 Slide 28 Growth opportunities supported by strong global presence in both sales and manufacturing FTEs in sales regions¹ North America Operations: Region Africa, Asia, Middle-East and Oceania (AAMEO): Region China: Region Europe: Region Japan & Korea: Region Latin America: Total non-HQ/manufacturing FTES: ~4,900 West Lebanon, NH, USA (~160)² ~4,500 Biopharmaceutical Global manufacturing setup Denmark (~9,500 FTEs) Diabetes and biopharmaceutical API production Filling Moulding and assembly Packaging Kaluga, Russia (~240 FTEs) Filling Assembly Packaging API production Koriyama, Japan (~70 FTEs) ~3,000 Packaging ~2,700 Clayton, NC, USA (~800 FTEs) Diabetes API production Filling Chartres, France (~1,100 FTEs) ~1,100 Assembly Packaging of above Tianjin, China (~1,000 FTEs) Filling Assembly Packaging Filling Moulding and Assembly Packaging ~850 Montes Claros, Brazil (~920 FTEs) ~17,000¹ Filling Assembly Packaging 1 FTEs represent full-time equivalents in Novo Nordisk's sales regions (excludes all other employees in headquarter, research sites and manufacturing sites) as of March 2017 2 New Hampshire facility is currently under establishment changing diabetes novo nordisk

View entire presentation